Klinische Studie KO-2806-001 – Harnorgane
Offizieller Studientitel: Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO 2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors DE ↗
Studieninformationen
- Phase
- Phase I
- Organsystem
- Harnorgane
- Histologischer Typ
- Karzinom
- Molekulare Marker
- –
- Therapiesetting
- Metastasiert
- Therapielinie
- 2nd line
- Pädiatrische Studie
- Nein
- Sponsor
- –
Register & Identifikatoren
- ClinicalTrials.gov
- –
- EudraCT-Nr.
- 2024-513285-19-00
Standort & Kontakt
- Standort
- –
- Klinische Fachabteilung
- Charité Comprehensive Cancer Center (CCCC)
- Prüfarzt (PI)
- Prof. Dr. Sebastian Ochsenreither
- Ansprechpartner
- –
- –
- Telefon
- –